Procaps Group Sa Stock Price, News & Analysis
Company Description
Procaps Group S.A. (PROCF) is described as an integrated international healthcare and pharmaceutical company that develops, manufactures, and commercializes pharmaceutical solutions across more than 50 markets. The company is associated with the Drug Manufacturers – Specialty & Generic industry within the broader healthcare sector, with a presence across Latin America and the United States.
According to the company, Procaps operates with a proprietary manufacturing platform and a broad portfolio of differentiated technologies. Its activities span the pharmaceutical value chain, from development and production to commercialization of healthcare and pharmaceutical products. The company highlights a focus on improving health and well-being globally through these solutions.
Business focus and geographic footprint
Procaps states that it has a presence across Latin America and the U.S., serving more than 50 markets. As part of a transformation process, the company has relocated its corporate headquarters to Bogotá, Colombia, while maintaining an operational presence in Barranquilla, Colombia, where manufacturing plants, product development, and other key operational teams remain based. Barranquilla is described as a critical hub for the company’s innovation and production.
To increase accountability and commercial performance, Procaps is reorganizing its operations into five regional clusters: Colombia; Brazil; United States; Andinos (Peru, Ecuador, Bolivia); and CENAM (Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama, and the Dominican Republic). This regional structure is intended to align the organization more closely with its core markets.
Capital structure and transformation strategy
The company has announced a multi-phase transformation strategy centered on growth, disciplined execution, and enhanced corporate governance. As part of this process, Procaps completed a private capital raise totaling $130 million, consisting of a private placement of ordinary shares and secured convertible notes that were later converted into ordinary shares. The investment was secured from a group of investors, including Chemo Project S.A., Becaril S.A., Flying Fish Ventures L.P., Saint Thomas Commercial S.A., Santana S.A., Hoche Partners Pharma Holding S.A. and others. This investor group collectively holds a substantial majority of the company’s shares.
In parallel, Procaps finalized a comprehensive restructuring of its debt with key lenders, including debt that had been subject to forbearance. The restructuring includes extensions of maturities, revised payment terms, reprofiling of obligations, and adjustments to covenants designed to align with the company’s operational turnaround timeline. Certain lenders agreed to convert a portion of their indebtedness into equity, aligning their interests with the company’s long-term plans.
Governance, controls, and organizational changes
The company describes a renewed focus on governance, compliance, and internal controls. It refers to a remediation plan related to findings from an internal investigation, aimed at addressing internal controls, governance, and financial reporting. The transformation includes centralization of finance, financial planning and analysis, compliance, legal, IT, and key support functions, alongside leadership transitions oriented toward performance and accountability.
Procaps has indicated that it is working on restating prior-period financial statements and releasing audited financials for past years as soon as reasonably practical. The company also mentions structural cost-efficiency measures, centralized decision-making to drive operating leverage, and prioritization of margin expansion through performance discipline and business simplification.
Strategic priorities and areas of focus
Within its broader healthcare and pharmaceutical activities, Procaps highlights several strategic priorities. These include restoring profitability through operational efficiency and cost control, reinforcing governance and transparency, and executing its remediation plan. The company also notes an intention to unlock value through divestitures of non-core assets and to focus on high-margin, strategic segments.
In terms of product and market orientation, Procaps points to a focus on prescription drugs (Rx) and on expanding its contract development and manufacturing organization (CDMO) global footprint. The company also states that it is actively evaluating strategic alternatives for non-core assets, with potential proceeds intended for deleveraging and reinvestment in high-margin, strategic assets and operations.
Position within the healthcare and pharmaceutical sector
Within the healthcare sector, Procaps presents itself as an integrated pharmaceutical and healthcare company with an international reach, a proprietary manufacturing platform, and differentiated technologies. Its regional clusters across Latin America and the U.S., combined with its emphasis on prescription drugs and CDMO activities, position it within the specialty and generic drug manufacturing space as defined by its industry classification.
The company’s recent capital restructuring, governance enhancements, and organizational realignment are described as key elements of a turnaround and transformation effort. These measures are intended to support long-term sustainability, cash flow flexibility, and the execution of its strategic plan, while maintaining its role in developing, manufacturing, and commercializing pharmaceutical solutions in its target markets.
Stock Performance
Procaps Group Sa (PROCF) stock last traded at $0.0251. Over the past 12 months, the stock has lost 95.3%. At a market capitalization of $58.4M, PROCF is classified as a micro-cap stock with approximately 2.3B shares outstanding.
PROCF Rankings
Latest News
Procaps Group Sa has 1 recent news article. View all PROCF news →
SEC Filings
Procaps Group Sa has filed 8 recent SEC filings, including 8 Form 3. The most recent filing was submitted on March 30, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all PROCF SEC filings →
Financial Highlights
Procaps Group Sa generated $373.8M in revenue over the trailing twelve months, and net income was -$68.3M, reflecting a -18.3% net profit margin. The company generated $88.4M in operating cash flow. With a current ratio of 0.52, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Procaps Group Sa (PROCF) currently stands at 27.6 thousand shares, down 0.5% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has decreased by 21.6%. This relatively low short interest suggests limited bearish sentiment. With 87.8 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for Procaps Group Sa (PROCF) currently stands at 87.8 days, down 91.2% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has decreased 20.4% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 4.6 to 1000.0 days.
PROCF Company Profile & Sector Positioning
Procaps Group Sa (PROCF) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing PROCF often look at related companies in the same sector, including Almirall (LBTSF), Almirall SA (ALMRY), Hypera Sa (HYPMY), Sumitomo Dainippon Pharma (SMDPY), and Hikma Pharmaceuticals Plc (HKMPY). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate PROCF's relative position within its industry.